Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 3
2004 4
2005 11
2006 8
2007 7
2008 8
2009 9
2010 4
2012 2
2013 7
2014 5
2015 7
2016 3
2017 7
2018 10
2019 2
2020 8
2021 26
2022 14
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Among authors: granito a. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Regorafenib for the treatment of hepatocellular carcinoma.
Tovoli F, Granito A, De Lorenzo S, Bolondi L. Tovoli F, et al. Among authors: granito a. Drugs Today (Barc). 2018 Jan;54(1):5-13. doi: 10.1358/dot.2018.54.1.2736667. Drugs Today (Barc). 2018. PMID: 29569657 Review.
COVID-19: Has the Liver Been Spared?
Brandi N, Spinelli D, Granito A, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. Brandi N, et al. Among authors: granito a. Int J Mol Sci. 2023 Jan 6;24(2):1091. doi: 10.3390/ijms24021091. Int J Mol Sci. 2023. PMID: 36674607 Free PMC article. Review.
TKIs in combination with immunotherapy for hepatocellular carcinoma.
Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, Granito A. Stefanini B, et al. Among authors: granito a. Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. doi: 10.1080/14737140.2023.2181162. Epub 2023 Feb 26. Expert Rev Anticancer Ther. 2023. PMID: 36794716 Review.
HCV and autoimmunity.
Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. Ferri S, et al. Among authors: granito a. Curr Pharm Des. 2008;14(17):1678-85. doi: 10.2174/138161208784746824. Curr Pharm Des. 2008. PMID: 18673191 Review.
Tocilizumab: From Rheumatic Diseases to COVID-19.
Raiteri A, Piscaglia F, Granito A, Tovoli F. Raiteri A, et al. Among authors: granito a. Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512. Curr Pharm Des. 2021. PMID: 33719967 Review.
Experience with regorafenib in the treatment of hepatocellular carcinoma.
Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Granito A, et al. Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959. doi: 10.1177/17562848211016959. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34104211 Free PMC article. Review.
Hepatitis C and autoreactivity.
Bianchi FB, Muratori P, Granito A, Pappas G, Ferri S, Muratori L. Bianchi FB, et al. Among authors: granito a. Dig Liver Dis. 2007 Sep;39 Suppl 1:S22-4. doi: 10.1016/s1590-8658(07)80006-5. Dig Liver Dis. 2007. PMID: 17936218 Review.
An update on atezolizumab for hepatocellular carcinoma.
Ielasi L, Sansone V, Forgione A, Granito A, Benevento F, Tovoli F. Ielasi L, et al. Among authors: granito a. Drugs Today (Barc). 2021 Jun;57(6):365-375. doi: 10.1358/dot.2021.57.6.3264116. Drugs Today (Barc). 2021. PMID: 34151903
148 results